Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 9

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  chronic rhinosinusitis
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Current issues in the diagnostics of paediatric chronic rhinosinusitis

100%
Standylo A., Obuchowska A., Horoch T., Mielnik-Niedzielska G.
Journal of Pre-Clinical and Clinical Research
|
2021
|
tom 15
|
nr 3
2

Epithelial–mesenchymal transition in chronic rhinosinusitis: differences revealed between epithelial cells from nasal polyps and inferior turbinates

100%
Konnecke M., Burmeister M., Pries R., Boscke R., Bruchhage K.-L., Ungefroren H., Klimek L., Wollenberg B.
Archivum Immunologiae et Therapiae Experimentalis
|
2017
|
tom 65
|
nr 2
3

The expression of bitter taste receptor TAS2R38 in patients with chronic rhinosinusitis

84%
Zborowska-Piskadlo K., Stachowiak M., Rusetska N., Sarnowska E., Siedlecki J., Dzaman K.
Archivum Immunologiae et Therapiae Experimentalis
|
2020
|
tom 68
|
nr 5
4

Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps

84%
Dzaman K., Szczepanski M. J., Molinska-Glura M., Krzeski A., Zagor M.
Archivum Immunologiae et Therapiae Experimentalis
|
2015
|
tom 63
|
nr 3
5

High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps

84%
Dzaman K., Zagor M., Molinska-Glura M., Krzeski A.
Folia Histochemica et Cytobiologica
|
2015
|
tom 53
|
nr 1
6

Neuronal differentiation capability of nasal polyps of chronic rhinosinusitis

84%
Koennecke M., Boscke R., Pfannerstill A.-C., Reers S., Elsner M., Fell B., Richter A., Bruchhage K.-L., Schumann S., Pries R., Klimek L., Wollenberg B.
Archivum Immunologiae et Therapiae Experimentalis
|
2017
|
tom 65
|
nr 5
7
Content available remote

Quercetin attenuates naso-sinusal inflammation and inflammatory response in lungs and brain on an experimental model of acute rhinosinusitis in rats

84%
Tiboc-Schnell C. N., Filip G. A., Man S. C., Decea N., Moldovan R., Opris R., Sas V., Tabaran F.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 4
8
Content available remote

Eicosanoids, aspirin-intolerance and the upper airways - current standards and recent improvements of the desensitization therapy

67%
Pfaar O., Klimek L.
Journal of Physiology and Pharmacology. Supplement
|
2006
|
tom 57
|
nr 12
5-13
In 1922, Widal et al. were the first to describe intolerance reactions to acetylsalicylic acid (ASA, e.g. in aspirin) and to other nonsteroidal anti-inflammatory drugs (NSAIDs). The full clinical picture reveals a classic triad of symptoms (Samters Triad): aspirin induced bronchial asthma (with severe acute asthma attacks), aspirin-sensitivity and chronic rhinosinusitis with nasal polyps. In many cases, nasal polyps reveal as the first symptom of ASA sensitivity indicating that the upper airways are predominantly involved in the pathogenetic process. Therefor, emphasis of this article mainly focuses on the upper airways in ASA-intolerant patients. In the last decade, clear evidence has been pointed out that ASA-intolerance is related to the abnormal metabolism of arachidonic acid leading towards excessive leukotriene (LTs) production. The resulting dysbalance of the eicosanoids leukotrien and prostaglandine might be the crucial pathophysiologic keypoint of the disease. The incidence of aspirin hypersensitivity in the general population ranges from 0.6 % to 2.5% and in adult astmatics from 4,3 % to 11%. Besides the patients history, challenge tests with Lysin-aspirin are performed as the diagnostic tool of choice. Apart from surgical or pharmacological therapy, ASA desensitization therapy is the only specific treatment of choice. As first described by Stevensson et al. in the early 1984, oral administration by means of an initial desensitization with gradually ascending doses of aspirin is followed by a daily maintenance-dose. In the last years, many publications on various desensitization protocols and routes of administration have been worked out. Recently, the intravenous route for the inititial increment desensitization has been described which might offer new therapeutical possibilities in the treatment of ASA-intolerant patients.
9

The presence of B7-H4+ macrophages and CD25+CD4+ and FOXP3+ regulatory T cells in the microenvironment of nasal polyps – a preliminary report

67%
Dutsch-Wicherek M., Tomaszewska R., Lazar A., Strek P., Wicherek L., Kijowski J., Majka M.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 4
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.